CIENCIASMEDICASNEWS: Accelerating COVID-19 Assay Preparation Using Parallel Evaporators

lunes, 4 de mayo de 2020

Accelerating COVID-19 Assay Preparation Using Parallel Evaporators

	Infectious Diseases
	The latest infectious diseases news from News Medical

Johns Hopkins researchers warn of new infectious diseases and death due to global warming

Accelerating COVID-19 Assay Preparation Using Parallel Evaporators

With confirmed infections surpassing 3.1 million worldwide and testing being a key component of restricting the spread of the disease, concentration on oligonucleotide synthesis is more important now than ever. The standard COVID-19 test is PCR made up of reagents, including primers and probes. As labs globally scale-up production of PCR test kits, workflow improvements are urgently needed. SP Scientific offers a range of evaporators that facilitate parallel evaporation in many different sample formats.

Find Out More

Coronavirus Antigen Array

Sino Biological's Sinommune™ is a multiplex assay platform for high-throughput serological studies. The product is designed for HTP serologic surveillance studies of SARS-CoV-2, SARS-CoV, MERS-CoV, common coronavirus, and other viruses that can cause upper respiratory infection.

Importance of Anti-Human Secondary Antibodies for Serological Testing

Learn how Jackson ImmunoResearch's Anti-Human antibodies can be used in the development and manufacture of serological tests critical in clinical decision-making. From SARS-CoV-2 tests used during the pandemic through to organ transplant screening, immunoassays are powerful and sensitive tests. Based on the highly specific binding between antibodies and antigens, they enable qualitative and quantitative detection of analytes even at low concentrations.

Learn More

	Genomic sequencing shows COVID-19 spread patterns Throughout the spread of the virus, genomic sequencing has played a role in epidemiologic tracking of the viral strains carried all over the world. Such strains are traced back to their origin by their unique mutations and help to link remote infections.

	Antibodies to COVID-19 present in only 2 to 3 percent of population This week on Monday (20th April 2020), in a press meet, the World Health Organization (WHO) Director-General said that only around 2 to 3 percent of the global population have antibodies that show they had been infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease.

	Scientists identify cells likely targeted by novel coronavirus Researchers at MIT; the Ragon Institute of MGH, MIT, and Harvard; and the Broad Institute of MIT and Harvard; along with colleagues from around the world have identified specific types of cells that appear to be targets of the coronavirus that is causing the Covid-19 pandemic.

	Hyperferritinemia associated with increased illness severity in COVID-19 Yehuda Shoenfeld is the world's leading expert in the research, treatment and prevention of autoimmune diseases.